Vivos Therapeutics specializes in diagnostic and treatment methods for patients suffering from dentofacial abnormalities, sleep apnea and snoring.
GM Instruments’ NR6 Rhinomanometer is the only FDA-approved four-phase rhinomanometer used to calculate nasal airway resistance.
The deal provides Vivos with a new revenue stream and a competitive advantage as the sole distributor of the product, chair and CEO Kirk Huntsman said in a June 29 news release.
